Among these, refractory seizures are particularly prevalent, affecting up to 70-90% of patients with low-grade gliomas due to the epileptogenic effects of the IDH mutation-driven oncometabolite 2-hydroxyglutarate (2-HG). The gene discussed is IDH1; the disease is central nervous system cancer.